Atomo Diagnostics Limited researches, designs, develops, manufactures, and sells medical devices for blood-based rapid testing for professional use and self-testing. More Details
Exceptional growth potential with excellent balance sheet.
Share Price & News
How has Atomo Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AT1's share price has been volatile over the past 3 months.
7 Day Return
AU Medical Equipment
1 Year Return
AU Medical Equipment
Return vs Industry: Insufficient data to determine how AT1 performed against the Australian Medical Equipment industry.
Return vs Market: Insufficient data to determine how AT1 performed against the Australian Market.
Price Volatility Vs. Market
How volatile is Atomo Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StWe're Not Worried About Atomo Diagnostics' (ASX:AT1) Cash Burn
1 month ago | Simply Wall StWhat Is The Ownership Structure Like For Atomo Diagnostics Limited (ASX:AT1)?
3 months ago | Simply Wall StWhen Can We Expect A Profit From Atomo Diagnostics Limited (ASX:AT1)?
Is Atomo Diagnostics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AT1 (A$0.32) is trading below our estimate of fair value (A$2.36)
Significantly Below Fair Value: AT1 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AT1 is unprofitable, so we can't compare its PE Ratio to the AU Medical Equipment industry average.
PE vs Market: AT1 is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AT1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AT1 is good value based on its PB Ratio (5.1x) compared to the AU Medical Equipment industry average (6.1x).
How is Atomo Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AT1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: AT1 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AT1's is expected to become profitable in the next 3 years.
Revenue vs Market: AT1's revenue (57.8% per year) is forecast to grow faster than the Australian market (4.6% per year).
High Growth Revenue: AT1's revenue (57.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AT1's Return on Equity is forecast to be high in 3 years time (31.4%)
How has Atomo Diagnostics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: AT1 is currently unprofitable.
Growing Profit Margin: AT1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if AT1's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare AT1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AT1 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (37.2%).
Return on Equity
High ROE: AT1 has a negative Return on Equity (-26.73%), as it is currently unprofitable.
How is Atomo Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: AT1's short term assets (A$33.1M) exceed its short term liabilities (A$1.5M).
Long Term Liabilities: AT1's short term assets (A$33.1M) exceed its long term liabilities (A$112.7K).
Debt to Equity History and Analysis
Debt Level: AT1 is debt free.
Reducing Debt: AT1 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AT1 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AT1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Atomo Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AT1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AT1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AT1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AT1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AT1's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. John Michael Kelly founded Atomo Diagnostics Ltd. in 2010 and serves as its Chief Executive Officer & Managing Director. Mr. Kelly has significant med-tech experience, having held senior operational an ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD434.50K) is above average for companies of similar size in the Australian market ($USD277.63K).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
|Founder||no data||AU$610.95k||1.31% |
|Non-Executive Director||4yrs||AU$31.95k||no data|
|Independent Non-Executive Director||0.67yr||AU$17.50k||0.013% |
|Independent Non-Executive Director||0.67yr||AU$17.50k||0.018% |
|Independent Non-Executive Chairman||6.75yrs||AU$54.27k||0.58% |
|Member of Advisory Board||no data||no data||no data|
Experienced Board: AT1's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: AT1 only recently listed within the past 12 months.
Atomo Diagnostics Limited's company bio, employee growth, exchange listings and data sources
- Name: Atomo Diagnostics Limited
- Ticker: AT1
- Exchange: ASX
- Founded: 2010
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$177.140m
- Shares outstanding: 562.35m
- Website: https://atomodiagnostics.com
- Atomo Diagnostics Limited
- Level 2
- 701-703 Parramatta Road
- New South Wales
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AT1||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Apr 2020|
|AT1||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Apr 2020|
Atomo Diagnostics Limited researches, designs, develops, manufactures, and sells medical devices for blood-based rapid testing for professional use and self-testing. The company offers AtomoRapid RDT platf ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/25 10:42|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.